UBS Warns of Broadband Profit Pressure from Ofcom Cuts, Backs Pharma with Novo Nordisk +0.77%
UBS•UBS warned that UK retail broadband pricing faces pressure from proposed Ofcom wholesale charge cuts, prompting it to maintain 'sell' ratings on BT Group and Vodafone. It also recommended European pharmaceutical stocks, citing a cleaner alternative to overheated AI names and noting a 0.77% rise in Novo Nordisk shares.
1. Broadband Pricing Pressure
UBS’s quarterly UK broadband and mobile pricing review flagged that proposed Ofcom cuts to wholesale charges will squeeze retail broadband margins. The bank responded by maintaining 'sell' ratings on BT Group and Vodafone, citing an intensifying cost structure and competitive pricing environment.
2. Shift into European Pharmaceuticals
In tandem with its telecom outlook, UBS recommended reallocating exposure to European pharmaceutical stocks as a defensive play against volatile AI sectors. Analysts highlighted names such as Novo Nordisk—whose shares rose 0.77%—pointing to more stable cash flows and attractive valuations.
3. Strategic Rationale
UBS argued that reduced wholesale pricing power for broadband providers necessitates fresh sector allocations to preserve returns. The bank views pharmaceutical firms as benefiting from predictable regulatory frameworks and steady demand, offering downside protection relative to growth-driven AI equities.
